and Arvinas’s first-generation and now-discontinued AR-degrader bavdegalutamide, shows Halda’s preclinical data. “Stay tuned” for more details on the structure, target and preclinical data ...

Two papers in Nature now reveal that a glue degrader and cancer mutations enable an E3 ligase to recognize the same target protein through a convergent binding mode, which could inform discovery ...

Several NVIDIA RTX 5090 GPUs were reportedly shipped with hardware specifications that did not match the advertised numbers. A member of the TechPowerUp forums discovered discrepancies in the ROP ...

Augmented reality (AR) headsets have evolved significantly in 2025, offering enhanced hardware, refined user experiences, and growing software ecosystems. While AR has long been a futuristic ...

Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to ...

In his assessment, Mr Burgess said Australia’s security environment would become “more dynamic, more diverse and more degraded” over the next five years. He said foreign intelligence ...

Merck Sharp & Dohme LLC patents report the development of proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase (Von Hippel-Lindau disease tumor suppressor [VHL] ligands) ...

A tree nursery established by members of Sengwer community in efforts to reclaim the degraded Embobut Forest in Elgeyo Marakwet County. The rehabilitation of the degraded Embobut Forest in Elgeyo ...

Consumer AR glasses could soon become a reality thanks to a breakthrough holographic chip from Swave. Lightweight, low-power, affordable AR glasses have thus far been a distant dream. The best ...

The androgen receptor (AR) on the X chromosome is a central driver in this process, activating genes that govern proliferation and survival. Mutations and amplifications of the AR are closely ...

At the forefront of Nurix's clinical pipeline is NX-5948, a BTK degrader that has demonstrated significant potential in treating Chronic Lymphocytic Leukemia (CLL) and other hematological ...

An Update on the PARP Inhibitor Olaparib in mCRPC Patients: Review of the Phase 2 Results & A First Look at the Phase 3 Study.